You are here: Home: BCU Surgeons 1 | 2006: John Mackey, MD: Select Publications

SELECT PUBLICATIONS

Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Joensuu H et al; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20. Abstract

Jonat W et al. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: A meta-analysis of the ARNO 95 Trial, ABCSG Trial 8, and the ITA Trial. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 18.

Piccart-Gebhart MJ et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER 2-positive breast cancer. N Engl J Med 2005;353(16):1659- 72. Abstract

Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract

Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 1.

 

 

Table of Contents Top of Page

Home · Search

Table of Contents

Editor’s Note:
Neil Love, MD

Patrick I Borgen, MD
- Select publications

J Michael Dixon, MD
- Select publications

John Mackey, MD
- Select publications

Clifford Hudis, MD
- Select publications

Faculty Disclosures

CME Information

Editor's Office

BCU Media Center
Download PDF
Listen to Audio Files
Read Previous Issues

 

Terms of Use/Disclaimer | Privacy Policy | Hardware/Software Requirements
Copyright © 2006 Research To Practice, All Rights Reserved